{
  "name": "21 CFR 601.12 reporting categories for changes to an approved BLA",
  "description": "Side-by-side comparison of the three reporting categories in 21 CFR 601.12 (major, moderate, minor): the regulatory paragraph, what must be filed, when distribution may occur, and the prescribed submission label. Compiled by CASRAI from the regulation text read on 2026-11-17.",
  "page": "https://casrai.org/guides/21-cfr-601-12",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-21T10:35:00Z",
  "temporalCoverage": "Regulation text as read 2026-11-17",
  "spatialCoverage": null,
  "columns": [
    {
      "name": "Category",
      "unit": "",
      "description": ""
    },
    {
      "name": "Paragraph",
      "unit": "",
      "description": ""
    },
    {
      "name": "Potential for adverse effect",
      "unit": "",
      "description": ""
    },
    {
      "name": "Filing",
      "unit": "",
      "description": ""
    },
    {
      "name": "Timing rule",
      "unit": "",
      "description": ""
    },
    {
      "name": "Prescribed label",
      "unit": "",
      "description": ""
    },
    {
      "name": "Example named in the regulation",
      "unit": "",
      "description": ""
    }
  ],
  "rows": [
    {
      "Category": "Major",
      "Paragraph": "601.12(b)",
      "Potential for adverse effect": "Substantial",
      "Filing": "Supplement",
      "Timing rule": "FDA approval must be obtained before distribution",
      "Prescribed label": "Prior Approval Supplement-Expedited Review Requested (only when expedited review is requested under (b)(4))",
      "Example named in the regulation": "Change in the cell line or establishment of a new master cell bank or seed"
    },
    {
      "Category": "Moderate",
      "Paragraph": "601.12(c)",
      "Potential for adverse effect": "Moderate",
      "Filing": "Supplement",
      "Timing rule": "Submitted at least 30 days before distribution; distribution not less than 30 days after FDA receipt unless FDA says otherwise",
      "Prescribed label": "Supplement—Changes Being Effected in 30 Days (or Supplement—Changes Being Effected if FDA allows immediate distribution under (c)(5))",
      "Example named in the regulation": "Replacing equipment with equipment of similar but not identical design and operating principle"
    },
    {
      "Category": "Minor",
      "Paragraph": "601.12(d)",
      "Potential for adverse effect": "Minimal",
      "Filing": "Annual report",
      "Timing rule": "Within 60 days of the anniversary date of approval, unless an alternative date is approved",
      "Prescribed label": "None prescribed in the paragraph",
      "Example named in the regulation": "Extending expiration dating from full shelf-life data under a protocol approved in the application"
    },
    {
      "Category": "Labeling, newly acquired information",
      "Paragraph": "601.12(f)(2)",
      "Potential for adverse effect": "Not applicable (labeling)",
      "Filing": "Supplement submitted when the change is made",
      "Timing rule": "Product may be distributed before approval",
      "Prescribed label": "Special Labeling Supplement—Changes Being Effected",
      "Example named in the regulation": "Adding or strengthening a contraindication, warning, precaution or adverse reaction"
    }
  ],
  "sources": [
    {
      "title": "Cornell LII: 21 CFR 601.12",
      "url": "https://www.law.cornell.edu/cfr/text/21/601.12",
      "accessed": "2026-11-17"
    }
  ]
}